Literature DB >> 2267495

Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer.

N Khardori1, L Elting, E Wong, B Schable, G P Bodey.   

Abstract

From December 1985 to May 1986, Xanthomonas maltophilia (formerly known as Pseudomonas maltophilia) was isolated at an increased rate at our institution; 52 isolates of X. maltophilia were obtained in cultures of clinical specimens from 38 patients during that time. The records of 35 of these patients form the basis of this study. Twelve (71%) of the 17 infected and nine (50%) of the 18 colonized patients had received or were receiving antimicrobial therapy. Eleven of 17 patients (three of seven with septicemia, three of five with pneumonia, three with urinary tract infection, and two with wound infection) responded to antimicrobial therapy. Microbiologic studies of the potential environmental sources revealed growth of X. maltophilia in two water faucets and in one water sample from the medical intensive care unit. X. maltophilia is emerging as an important nosocomial pathogen in immunocompromised patients, especially those receiving broad-spectrum antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2267495     DOI: 10.1093/clinids/12.6.997

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  44 in total

1.  In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia.

Authors:  A Giacometti; O Cirioni; M S Del Prete; F Barchiesi; M Fortuna; D Drenaggi; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

2.  Pseudo-, Xantho-, and now Stenotrophomonas maltophilia: New kid on the block.

Authors:  J Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1996-03

3.  Antibiotic resistance of Stenotrophomonas maltophilia strains isolated from captive snakes.

Authors:  P Hejnar; M Kolár; P Sauer
Journal:  Folia Microbiol (Praha)       Date:  2010-03-25       Impact factor: 2.099

4.  Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997-2004.

Authors:  G Aisenberg; K V Rolston; B F Dickey; D P Kontoyiannis; I I Raad; A Safdar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-01       Impact factor: 3.267

5.  Molecular dynamic simulations of the metallo-beta-lactamase from Bacteroides fragilis in the presence and absence of a tight-binding inhibitor.

Authors:  Freddie R Salsbury; Michael W Crowder; Stephen F Kingsmore; James J A Huntley
Journal:  J Mol Model       Date:  2008-11-28       Impact factor: 1.810

6.  Chronic dacryocystitis secondary to Stenotrophomonas maltophilia and Staphylococcus aureus mixed infection.

Authors:  Arzu Taskiran Comez; Asiye Koklu; Alper Akcali
Journal:  BMJ Case Rep       Date:  2014-06-20

Review 7.  Infective endocarditis due to Stenotrophomonas (Xanthomonas) maltophilia.

Authors:  R G Munter; A M Yinnon; Y Schlesinger; C Hershko
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-05       Impact factor: 3.267

8.  Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment.

Authors:  F P Laing; K Ramotar; R R Read; N Alfieri; A Kureishi; E A Henderson; T J Louie
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

9.  Diversity of nosocomial Xanthomonas maltophilia (Stenotrophomonas maltophilia) as determined by ribotyping.

Authors:  P Gerner-Smidt; B Bruun; M Arpi; J Schmidt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-02       Impact factor: 3.267

10.  Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.